In addition, testing took place within NHS laboratories, with our results therefore reflecting how the Newcastle MSI-Plus assay would perform if adopted for routine urothelial carcinoma surveillance of individuals with a diagnosis of MSH2-Lynch syndrome or for MMRd testing of unselected UTUC. This evidence concerns the gene MSH2 and urothelial carcinoma.